<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>IDELALISIB - Research Report</title>
    <meta name="description" content="Comprehensive naturopathic research report for IDELALISIB">
    <style>

    * {
        box-sizing: border-box;
    }

    body {
        font-family: 'Segoe UI', 'Helvetica Neue', Arial, sans-serif;
        font-size: 16px;
        line-height: 1.6;
        margin: 0;
        padding: 0;
        background-color: #f8f9fa;
        color: #212529;
    }

    .container {
        max-width: 1200px;
        margin: 0 auto;
        padding: 20px;
        background-color: white;
        box-shadow: 0 0 10px rgba(0,0,0,0.1);
    }

    .medication-header {
        background: linear-gradient(135deg, #2c3e50, #003366);
        color: white;
        padding: 30px;
        margin: -20px -20px 30px -20px;
        border-radius: 0 0 10px 10px;
        text-align: center;
        position: relative;
    }

    .medication-header h1 {
        margin: 0 0 15px 0;
        font-size: 2.5em;
        font-weight: 600;
        text-shadow: 0 2px 4px rgba(0,0,0,0.3);
    }

    .status-badge {
        display: inline-block;
        padding: 8px 20px;
        border-radius: 25px;
        font-weight: 600;
        font-size: 0.9em;
        text-transform: uppercase;
        letter-spacing: 1px;
        box-shadow: 0 2px 4px rgba(0,0,0,0.2);
    }

    .status-allowed { background-color: #28a745; color: white; }
    .status-not-allowed { background-color: #dc3545; color: white; }
    .status-modernization { background-color: #fd7e14; color: white; }
    .status-topical { background-color: #20c997; color: white; }
    .status-review { background-color: #ffc107; color: #212529; }
    .status-not-applicable { background-color: #6c757d; color: white; }
    .status-unknown { background-color: #adb5bd; color: white; }

    .natural-connections {
        margin-bottom: 30px;
        padding: 20px;
        background-color: #f8f9fa;
        border-radius: 10px;
        border-left: 4px solid #007bff;
    }

    .natural-connections h2 {
        margin: 0 0 15px 0;
        font-size: 1.4em;
        color: #2c3e50;
    }

    .connection-tags {
        display: flex;
        flex-wrap: wrap;
        gap: 8px;
    }

    .connection-tag {
        display: inline-block;
        padding: 6px 12px;
        border-radius: 15px;
        font-size: 0.85em;
        font-weight: 500;
        color: white;
        white-space: nowrap;
    }

    .tag-direct { background-color: #0d6832; }
    .tag-semi-synthetic { background-color: #198754; }
    .tag-structural { background-color: #0d6efd; }
    .tag-endogenous { background-color: #6610f2; }
    .tag-biosynthetic { background-color: #6f42c1; }
    .tag-pathways { background-color: #0dcaf0; color: #212529; }
    .tag-processes { background-color: #3dd5f3; color: #212529; }

    .report-content {
        line-height: 1.7;
    }

    .report-content h1 {
        color: #2c3e50;
        border-bottom: 3px solid #007bff;
        padding-bottom: 10px;
        margin: 30px 0 20px 0;
    }

    .report-content h2 {
        color: #495057;
        border-bottom: 2px solid #dee2e6;
        padding-bottom: 8px;
        margin: 25px 0 15px 0;
    }

    .report-content h3 {
        color: #6c757d;
        margin: 20px 0 10px 0;
    }

    .report-content p {
        margin-bottom: 15px;
        text-align: justify;
    }

    .checkbox {
        font-weight: bold;
        margin-right: 5px;
    }

    .checkbox.checked { color: #28a745; }
    .checkbox.unchecked { color: #6c757d; }

    .footer {
        margin-top: 40px;
        padding: 20px 0;
        border-top: 1px solid #dee2e6;
        text-align: center;
        color: #6c757d;
        font-size: 0.9em;
    }

    .back-link {
        display: inline-block;
        margin-bottom: 20px;
        padding: 8px 16px;
        background-color: #007bff;
        color: white;
        text-decoration: none;
        border-radius: 5px;
        transition: background-color 0.3s;
    }

    .back-link:hover {
        background-color: #0056b3;
        text-decoration: none;
    }

    @media (max-width: 768px) {
        .container {
            padding: 15px;
            margin: 10px;
        }
        .medication-header {
            margin: -15px -15px 20px -15px;
            padding: 20px;
        }
        .medication-header h1 {
            font-size: 2em;
        }
        .connection-tags {
            justify-content: center;
        }
    }

    @media print {
        .back-link { display: none; }
        .container { box-shadow: none; }
        .medication-header {
            background: #2c3e50 !important;
            -webkit-print-color-adjust: exact;
        }
    }

    </style>
</head>
<body>
    <div class="container">
        <a href="index.html" class="back-link">← Back to Index</a>

        <header class="medication-header">
            <h1>IDELALISIB</h1>
            <div class="status-badge status-modernization">
                TARGET_FOR_MODERNIZATION
            </div>
        </header>

        <section class="natural-connections">
            <h2>Natural Connections</h2>
            <div class="connection-tags">
                <span class="connection-tag tag-pathways">Works Natural Pathways</span>
<span class="connection-tag tag-processes">Facilitates Natural Processes</span>
            </div>
        </section>

        <main class="report-content">
            <p>Naturopathic Formulary Medication Evaluation Protocol</p>

<p># Objective: Comprehensive assessment of natural derivation and therapeutic alignment For <strong>IDELALISIB</strong>: ## <h2>1. NATURAL DERIVATION ASSESSMENT</h2></p>

<p>### <h3>Source Investigation</h3> Idelalisib functions as a highly selective inhibitor of phosphoinositide 3-kinase delta (PI3K-δ), an enzyme that plays a crucial role in B-cell and T-cell signaling pathways. Idelalisib selectively regulates the delta isoform of phosphoinositide 3-kinase (PI3K-δ), which is predominantly expressed in hematopoietic cells. While developed through modern medicinal chemistry, the medication was intentionally crafted to engage these conserved pathways so clinicians can modulate them in a targeted way. Idelalisib is a synthetic small molecule inhibitor developed through pharmaceutical research. It is not directly isolated from natural sources such as plants, fungi, or marine organisms. There is no documented traditional medicine use of idelalisib or structurally identical compounds. The medication is produced through synthetic organic chemistry methods rather than fermentation or biosynthetic pathways.</p>

<h3>Structural Analysis</h3> Idelalisib (C22H18FN7O) is a quinazolinone derivative with a complex heterocyclic structure. While it works to directly mirror naturally occurring compounds, it contains structural motifs found in nature, including purine-like rings and aromatic systems. The compound shares some structural similarity with naturally occurring purines and quinazoline alkaloids found in various plant species, though it represents a highly modified synthetic analog designed for specific target selectivity.

<h3>Biological Mechanism Evaluation</h3> Idelalisib functions as a highly selective inhibitor of phosphoinositide 3-kinase delta (PI3K-δ), an enzyme that plays a crucial role in B-cell and T-cell signaling pathways. PI3K-δ is an endogenous human enzyme involved in normal immune system regulation, cell survival, and proliferation. The medication works by binding to the ATP-binding pocket of this naturally occurring enzyme, effectively modulating endogenous signaling cascades that regulate lymphocyte function.

<h3>Natural System Integration</h3> (Expanded Assessment) Idelalisib targets the naturally occurring PI3K-δ enzyme, which is part of evolutionarily conserved cellular signaling pathways present across species. The PI3K pathway represents one of the most fundamental cellular regulatory systems, controlling cell growth, survival, and metabolism. By selectively inhibiting PI3K-δ, idelalisib modulates endogenous immune cell function and can help restore balance in dysregulated B-cell populations. The medication works within existing cellular machinery and biochemical pathways rather than introducing foreign mechanisms. It enables the natural process of apoptosis (programmed cell death) in malignant B-cells while preserving normal cellular functions in other tissues.

<h2>2. THERAPEUTIC CONTEXT</h2>

<p>### Mechanism of Action Idelalisib selectively regulates the delta isoform of phosphoinositide 3-kinase (PI3K-δ), which is predominantly expressed in hematopoietic cells. This inhibition modulates key survival and proliferation signals in B-cells, leading to apoptosis of malignant cells. The PI3K-δ pathway is integral to B-cell receptor signaling, chemokine-directed cell migration, and cell adhesion. By blocking this pathway, idelalisib interferes with the survival mechanisms that allow certain blood cancers to persist and proliferate.</p>

<h3>Clinical Utility</h3> Idelalisib is FDA-approved for treatment of relapsed chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma, and relapsed small lymphocytic lymphoma. It is used in combination with rituximab for CLL and as monotherapy for lymphomas. The medication provides an oral treatment option for patients with limited alternatives, particularly those who serves to tolerate more intensive chemotherapy regimens. Common adverse effects include diarrhea, fatigue, nausea, and increased infection risk due to immunosuppression.

<h3>Integration Potential</h3> Given its mechanism as a targeted therapy for hematologic malignancies, idelalisib requires careful integration within comprehensive treatment plans. The medication can potentially create therapeutic windows during which supportive naturopathic interventions might be employed to maintain overall health and immune function. Additionally, extensive practitioner education would be essential due to the medication&#x27;s immunosuppressive effects and potential for serious adverse reactions.

<h2>3. REGULATORY AND PRECEDENT CONTEXT</h2>

<p>### Current Status Idelalisib received FDA approval in 2014 under the brand name Zydelig. It is classified as a kinase inhibitor and antineoplastic agent. The medication has been approved by the European Medicines Agency (EMA) and other international regulatory bodies for similar indications. It is not currently listed on the WHO Essential Medicines List, which typically focuses on more broadly applicable medications.</p>

<h3>Comparable Medications</h3> Currently, there are no directly comparable PI3K inhibitors in naturopathic formularies. Additionally, the concept of targeted enzyme inhibition is present with other medications that may be considered, such as certain natural product-derived compounds that modulate specific cellular pathways. The precedent for including synthetic medications that work through natural enzyme systems exists in various formulary contexts.

<h3>Formulary Precedent Analysis</h3>

<p>This medication aligns with established formulary principles that recognize both naturally-derived and laboratory-produced compounds when they demonstrate therapeutic value and integration with physiological systems. Similar to synthetic hormones already included in the formulary (ethinyl estradiol, levothyroxine), this medication demonstrates that production method works to preclude formulary inclusion when the therapeutic mechanism aligns with natural physiological processes. The precedent established by medications like tretinoin, sucralfate, and cholestyramine supports inclusion of compounds that work through natural pathways regardless of their origin.</p>

<h2>4. COMPREHENSIVE ASSESSMENT</h2> <strong>IDELALISIB</strong> <p><strong><strong>Evidence Categories Present:</strong></strong></p>

<ul>

<li><span class="checkbox unchecked"><span class="checkbox unchecked">☐</span> </span> Direct natural source</li>

<li><span class="checkbox unchecked"><span class="checkbox unchecked">☐</span> </span> Semi-synthetic from natural precursor</li>

<li><span class="checkbox unchecked"><span class="checkbox unchecked">☐</span> </span> Structural analog of natural compound</li>

<li><span class="checkbox unchecked"><span class="checkbox unchecked">☐</span> </span> Endogenous compound or replacement</li>

<li><span class="checkbox unchecked"><span class="checkbox unchecked">☐</span> </span> Biosynthetic/fermentation product</li>

<li><span class="checkbox checked">✓</span> Works through natural pathways/receptors</li>

<li><span class="checkbox checked">✓</span> Facilitates natural physiological processes</li>

<li><span class="checkbox unchecked"><span class="checkbox unchecked">☐</span> </span> No identified natural connection</li>

</ul><p><strong>Natural Derivation Assessment:</strong></p>

<p>Idelalisib is a laboratory-produced compound without direct natural source derivation. Additionally, it contains structural elements reminiscent of naturally occurring purines and quinazoline alkaloids. The primary natural connection lies in its interaction with endogenous enzyme systems rather than its structural origin.</p><p><strong>Structural/Functional Relationships:</strong></p>

<p>While structurally synthetic, idelalisib targets the naturally occurring PI3K-δ enzyme, which is part of fundamental cellular signaling pathways. The compound&#x27;s quinazolinone core shares some structural features with natural heterocyclic compounds, though it represents a highly modified synthetic design optimized for enzyme selectivity.</p><p><strong>Biological Integration:</strong></p>

<p>Idelalisib integrates with natural cellular systems by specifically binding to the ATP-binding site of PI3K-δ, an endogenous enzyme crucial for B-cell and T-cell function. This interaction modulates naturally occurring signal transduction pathways, affecting cell survival, proliferation, and apoptosis through existing cellular machinery.</p><p><strong>Natural System Interface:</strong></p>

<p>The medication works entirely within naturally occurring biological systems, specifically targeting evolutionarily conserved PI3K signaling pathways. By inhibiting PI3K-δ, it enables natural apoptotic processes in malignant B-cells while working through endogenous cellular death mechanisms. This represents restoration of normal cellular regulation rather than introduction of foreign biological processes.</p><p><strong>Safety and Therapeutic Profile:</strong></p>

<p>Idelalisib provides an oral targeted therapy option for relapsed hematologic malignancies, potentially offering less systemic toxicity than traditional cytotoxic chemotherapy. Additionally, it carries risks of serious immune-related adverse effects including severe diarrhea, hepatotoxicity, and increased infection susceptibility due to its immunosuppressive mechanism.</p><p><strong>Summary of Findings:</strong></p>

<p>IDELALISIB demonstrates significant therapeutic value through integration with natural physiological systems. The medication&#x27;s immune effects work through established biological pathways, supporting the body&#x27;s inherent healing processes. Evidence supports inclusion in the naturopathic formulary based on demonstrated therapeutic efficacy, safety profile, and alignment with principles of supporting natural healing. The medication fills a critical therapeutic need while maintaining compatibility with naturopathic treatment approaches.</p><p><strong><strong>Relevant Citations:</strong></strong></p>

<ol>

<li>Available at: https://go.drugbank.com/drugs/DB09053</li>

<li>FDA. &quot;Zydelig (idelalisib) tablets, for oral use. Prescribing Information.&quot; Gilead Sciences, Inc. Initial approval July 2014, Revised October</li>

<li>Furman RR, Sharman JP, Coutre SE, et al. &quot;Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.&quot; New England Journal of Medicine. 2014;370(11):997-1007. DOI: 10.1056/NEJMoa1315226</li>

<li>PubChem. &quot;Idelalisib&quot; PubChem CID</li>

<li>National Center for Biotechnology Information, National Library of Medicine. Available at: https://pubchem.ncbi.nlm.nih.gov/compound/11625818</li>

<li>Brown JR, Byrd JC, Coutre SE, et al. &quot;Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.&quot; Blood. 2014;123(22):3390-3397. DOI: 10.1182/blood-2013-11-535047</li>

<li>Vanhaesebroeck B, Guillermet-Guibert J, Graupera M, Bilanges B. &quot;The emerging mechanisms of isoform-specific PI3K signalling.&quot; Nature Reviews Molecular Cell Biology. 2010;11(5):329-341. DOI: 10.1038/nrm2882</li>

<li>Lampson BL, Brown JR. &quot;PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.&quot; Expert Opinion on Investigational Drugs. 2017;26(11):1267-1279. DOI: 10.1080/13543784.2017.1384815</li>

</ol>
        </main>

        <footer class="footer">
            <p>Generated on September 24, 2025 at 07:19 AM</p>
        </footer>
    </div>
</body>
</html>